Related references
Note: Only part of the references are listed.Pre-existing polymerase-specific T cells expand in abortive seronegative SARS-CoV-2
Leo Swadling et al.
NATURE (2022)
Tuberculosis vaccine BCG: the magical effect of the old vaccine in the fight against the COVID-19 pandemic
Ashok Aspatwar et al.
INTERNATIONAL REVIEWS OF IMMUNOLOGY (2022)
Genomic surveillance to combat COVID-19: challenges and opportunities
Janet Robishaw et al.
LANCET MICROBE (2021)
Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK
Merryn Voysey et al.
LANCET (2021)
FAST-SPREADING COVID VARIANT CAN ELUDE IMMUNE RESPONSES
Ewen Callaway
NATURE (2021)
Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection
Jennifer M. Dan et al.
SCIENCE (2021)
SARS-CoV-2 spike glycoprotein vaccine candidate NVX-CoV2373 immunogenicity in baboons and protection in mice
Jing-Hui Tian et al.
NATURE COMMUNICATIONS (2021)
Emergence of SARS-CoV-2 B.1.1.7 Lineage — United States, December 29, 2020–January 12, 2021
Summer E. Galloway et al.
MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT (2021)
SARS-CoV-2 variant B.1.1.7 is susceptible to neutralizing antibodies elicited by ancestral spike vaccines
Xiaoying Shen et al.
CELL HOST & MICROBE (2021)
SARS-CoV-2 re-infection risk in Austria
Stefan Pilz et al.
EUROPEAN JOURNAL OF CLINICAL INVESTIGATION (2021)
Immunogenicity of the Ad26.COV2.S Vaccine for COVID-19
Kathryn E. Stephenson et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2021)
A Novel Soluble ACE2 Variant with Prolonged Duration of Action Neutralizes SARS-CoV-2 Infection in Human Kidney Organoids
Jan Wysocki et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2021)
Challenges in ensuring global access to COVID-19 vaccines: production, affordability, allocation, and deployment
Olivier J. Wouters et al.
LANCET (2021)
Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials
Merryn Voysey et al.
LANCET (2021)
Resurgence of COVID-19 in Manaus, Brazil, despite high seroprevalence
Ester C. Sabino et al.
LANCET (2021)
Furin cleavage of the SARS-CoV-2 spike is modulated by O-glycosylation
Liping Zhang et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2021)
Sensitivity of SARS-CoV-2 B.1.1.7 to mRNA vaccine-elicited antibodies
Dami A. Collier et al.
NATURE (2021)
The coronavirus is here to stay - here's what that means
Nicky Phillips
NATURE (2021)
Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7
Pengfei Wang et al.
NATURE (2021)
Could mutations of SARS-CoV-2 suppress diagnostic detection?
Carl A. Ascoli
NATURE BIOTECHNOLOGY (2021)
Early lab studies shed light on Omicron’s behavior
Gretchen Vogel et al.
SCIENCE (2021)
The commitment for fair distribution of COVID-19 vaccine among all countries of the world
Reza Sadeghi et al.
RESEARCH IN NURSING & HEALTH (2021)
Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England
Nicholas G. Davies et al.
SCIENCE (2021)
Inhibitors of endosomal acidification suppress SARS-CoV-2 replication and relieve viral pneumonia in hACE2 transgenic mice
Chao Shang et al.
VIROLOGY JOURNAL (2021)
Covid-19: WHO warns against vaccine nationalism or face further virus mutations
Lynn Eaton
BMJ-BRITISH MEDICAL JOURNAL (2021)
Covid-19: Novavax vaccine efficacy is 86% against UK variant and 60% against South African variant
Elisabeth Mahase
BMJ-BRITISH MEDICAL JOURNAL (2021)
Targeting androgen regulation of TMPRSS2 and ACE2 as a therapeutic strategy to combat COVID-19
Qu Deng et al.
ISCIENCE (2021)
Covid-19: Omicron may be more transmissible than other variants and partly resistant to existing vaccines, scientists fear
Ingrid Torjesen
BMJ-BRITISH MEDICAL JOURNAL (2021)
Covid-19: Hospital admission 50-70% less likely with omicron than delta, but transmission a major concern
Elisabeth Mahase
BMJ-BRITISH MEDICAL JOURNAL (2021)
Transmission, infectivity, and neutralization of a spike L452R SARS-CoV-2 variant
Xianding Deng et al.
CELL (2021)
Increased resistance of SARS-CoV-2 variant P.1 to antibody neutralization
Pengfei Wang et al.
CELL HOST & MICROBE (2021)
The Potential Future of the COVID-19 Pandemic Will SARS-CoV-2 Become a Recurrent Seasonal Infection?
Christopher J. L. Murray et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2021)
Higher infectivity of the SARS-CoV-2 new variants is associated with K417N/T, E484K, and N501Y mutants: An insight from structural data
Abbas Khan et al.
JOURNAL OF CELLULAR PHYSIOLOGY (2021)
The Disease Severity and Clinical Outcomes of the SARS-CoV-2 Variants of Concern
Lixin Lin et al.
FRONTIERS IN PUBLIC HEALTH (2021)
Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trial
Katherine R. W. Emary et al.
LANCET (2021)
‘Unprecedented achievement’: who received the first billion COVID vaccinations?
Freda Kreier
NATURE (2021)
Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant
S. A. Madhi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Efficacy of NVX-CoV2373 Covid-19 Vaccine against the B.1.351 Variant
V. Shinde et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
New challenges to fighting COVID-19: Virus variants, potential vaccines, and development of antivirals
Jun Chen et al.
BIOSCIENCE TRENDS (2021)
COVID-19 Vaccines: Current Understanding on Immunogenicity, Safety, and Further Considerations
Qian He et al.
FRONTIERS IN IMMUNOLOGY (2021)
Mini-Review Discussing the Reliability and Efficiency of COVID-19 Vaccines
Bogdan Doroftei et al.
DIAGNOSTICS (2021)
COVID-19 pandemic: SARS-CoV-2 specific vaccines and challenges, protection via BCG trained immunity, and clinical trials
Wenping Gong et al.
EXPERT REVIEW OF VACCINES (2021)
Acquisition of the L452R Mutation in the ACE2-Binding Interface of Spike Protein Triggers Recent Massive Expansion of SARS-CoV-2 Variants
Veronika Tchesnokova et al.
JOURNAL OF CLINICAL MICROBIOLOGY (2021)
Neutralising antibody activity against SARS-CoV-2 VOCs B.1.617.2 and B.1.351 by BNT162b2 vaccination
Emma C. Wall et al.
LANCET (2021)
The SARS-CoV-2 B.1.1.7 variant and increased clinical severity-the jury is out
Benjamin Giles et al.
LANCET INFECTIOUS DISEASES (2021)
Mortality and critical care unit admission associated with the SARS-CoV-2 lineage B.1.1.7 in England: an observational cohort study
Martina Patone et al.
LANCET INFECTIOUS DISEASES (2021)
Highly accurate protein structure prediction with AlphaFold
John Jumper et al.
NATURE (2021)
The next phase of SARS-CoV-2 surveillance: real-time molecular epidemiology
Bas B. Oude Munnink et al.
NATURE MEDICINE (2021)
Understanding COVID-19 vaccine hesitancy
Shingai Machingaidze et al.
NATURE MEDICINE (2021)
Safety, Immunogenicity, and Efficacy of the BNT162b2 Covid-19 Vaccine in Adolescents
Robert W. Frenck et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Safety and Efficacy of NVX-CoV2373 Covid-19 Vaccine
Paul T. Heath et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
New variants of SARS-CoV-2
Rafael Canton et al.
REVISTA ESPANOLA DE QUIMIOTERAPIA (2021)
Covid-19: Local councils initiate surge vaccination to tackle B.1.617.2 variant
Gareth Iacobucci
BMJ-BRITISH MEDICAL JOURNAL (2021)
Effectiveness of booster BCG vaccination in preventing Covid-19 infection
Lradj Amirlak et al.
HUMAN VACCINES & IMMUNOTHERAPEUTICS (2021)
SARS-CoV-2 B.1.617.2 (Delta) Variant COVID-19 Outbreak Associated with a Gymnastics Facility — Oklahoma, April–May 2021
Kendra Dougherty et al.
MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT (2021)
SARS-CoV-2 Spike Mutations, L452R, T478K, E484Q and P681R, in the Second Wave of COVID-19 in Maharashtra, India
Sarah Cherian et al.
MICROORGANISMS (2021)
Severe SARS-CoV-2 Breakthrough Reinfection With Delta Variant After Recovery From Breakthrough Infection by Alpha Variant in a Fully Vaccinated Health Worker
Jayanthi Shastri et al.
FRONTIERS IN MEDICINE (2021)
Emerging SARS-CoV-2 B.1.621/Mu variant is prominently resistant to inactivated vaccine-elicited antibodies
Xiaochun Xie et al.
ZOOLOGICAL RESEARCH (2021)
Confirmed Reinfection With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Variant VOC-202012/01
David Harrington et al.
CLINICAL INFECTIOUS DISEASES (2021)
Impact of original, B.1.1.7, and B.1.351/P.1 SARS-CoV-2 lineages on vaccine effectiveness of two doses of COVID-19 mRNA vaccines: Results from a nationwide case-control study in France
Tiffany Charmet et al.
LANCET REGIONAL HEALTH-EUROPE (2021)
A look into the future of the COVID-19 pandemic in Europe: an expert consultation
Emil Nafis Iftekhar et al.
LANCET REGIONAL HEALTH-EUROPE (2021)
SARS-CoV-2 B.1.617.2 Delta variant replication and immune evasion
Petra Mlcochova et al.
NATURE (2021)
Serosurvey in BNT162b2 vaccine-elicited neutralizing antibodies against authentic B.1, B.1.1.7, B.1.351, B.1.525 and P.1 SARS-CoV-2 variants
Alberto Zani et al.
EMERGING MICROBES & INFECTIONS (2021)
Emerging SARS-CoV-2 variants of concern and potential intervention approaches
Jasmin Khateeb et al.
CRITICAL CARE (2021)
SARS-CoV-2 spike E484K mutation reduces antibody neutralisation
Sonia Jangra et al.
LANCET MICROBE (2021)
Will Mutations in the Spike Protein of SARS-CoV-2 Lead to the Failure of COVID-19 Vaccines?
Zaixing Jia et al.
JOURNAL OF KOREAN MEDICAL SCIENCE (2021)
Transmission of SARS-CoV-2 on mink farms between humans and mink and back to humans
Bas B. Oude Munnink et al.
SCIENCE (2021)
Viral targets for vaccines against COVID-19
Lianpan Dai et al.
NATURE REVIEWS IMMUNOLOGY (2021)
Comparison of the immunogenicity & protective efficacy of various SARS-CoV-2 vaccine candidates in non-human primates
Labanya Mukhopadhyay et al.
INDIAN JOURNAL OF MEDICAL RESEARCH (2021)
Development of CRISPR as an Antiviral Strategy to Combat SARS-CoV-2 and Influenza
Timothy R. Abbott et al.
CELL (2020)
Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein
Alexandra C. Walls et al.
CELL (2020)
Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19) A Review
James M. Sanders et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2020)
Developing Covid-19 Vaccines at Pandemic Speed
Nicole Lurie et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
The Impact of Mutations in SARS-CoV-2 Spike on Viral Infectivity and Antigenicity
Qianqian Li et al.
CELL (2020)
Evidence for SARS-CoV-2 Infection of Animal Hosts
Ahmed S. Abdel-Moneim et al.
PATHOGENS (2020)
Mutations Strengthened SARS-CoV-2 Infectivity
Jiahui Chen et al.
JOURNAL OF MOLECULAR BIOLOGY (2020)
Antibody cocktail to SARS-CoV-2 spike protein prevents rapid mutational escape seen with individual antibodies
Alina Baum et al.
SCIENCE (2020)
Phase 1-2 Trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine
Cheryl Keech et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
REGN-COV2 antibodies prevent and treat SARS-CoV-2 infection in rhesus macaques and hamsters
Alina Baum et al.
SCIENCE (2020)
NVX-CoV2373 vaccine protects cynomolgus macaque upper and lower airways against SARS-CoV-2 challenge
Mimi Guebre-Xabier et al.
VACCINE (2020)
Is the tuberculosis vaccine BCG an alternative weapon for developing countries to defeat COVID-19?
Wenping Gong et al.
Indian Journal of Tuberculosis (2020)
Robust neutralizing antibodies to SARS-CoV-2 infection persist for months
Ania Wajnberg et al.
SCIENCE (2020)
Vaccine hesitancy: Definition, scope and determinants
Noni E. MacDonald
VACCINE (2015)
Newly Emerging Mutations in the Matrix Genes of the Human Influenza A(H1N1)pdm09 and A(H3N2) Viruses Reduce the Detection Sensitivity of Real-Time Reverse Transcription-PCR
Ji-Rong Yang et al.
JOURNAL OF CLINICAL MICROBIOLOGY (2014)